-
Oral and Poster Presentation at IPA 2025 Congress in Shanghai – Plasmonic Photothermal Therapy for Melanoma Treatment
Elyas Al Yasini, a CIFRE PhD student at the OncoThAI research unit (INSERM U1189), in collaboration with the company TORSKAL based in La Réunion, has been selected to present both an oral [...]
-
Defense of Léa Boidin thesis - November 26, 2024
Léa Boidin defended her PhD thesis entitled « Proposal of a Photodynamic Therapy targeting FRα for the treatment of microscopic metastases of epithelial ovarian cancers: Preclinical [...]
-
Defense of Camille Triöen thesis - November 27, 2024
Camille Triöen defended her PhD thesis entitled « Evaluation of novel therapeutic strategies targeting tumour-derived exosomes in nasopharyngeal carcinoma (NPC): Proposal for an [...]
Clinical tests
Enrollment phase of INDYGO is now successfully achieved
After the inclusion of 10 patients, the first step of the INDYGO study is now completed, enabling the analysis of data collected during the trial
Rare diseases foundation and OncoThAI
OncoThAI and the Photodynamic Therapy Awarded by the french Rare Diseases foundation and SATT Nord
Photodynamic Therapy and OncoThAI illustrated in Nature journal
The INDYGO clinical trial by OncoThAI described in the last issue of the Nature Journal
Authorizations for the PAGETEX clinical trial
The French regulatory agencies (ANSM and CPP) authorize our clinical trial on the photodynamic treatment of the Paget's disease.
End of the evaluation of the PHOSISTOS® project
Evaluation of the PHOS-ISTOS® project completed, with a very favorable opinion from the European Commission
Start of the PAGETEX clinical trial
The first patient with Paget's disease has been treated by the PAGETEX clinical protocol.
